GO
Loading...

CV Therapeutics Angina Drug Not Effective in Study; Shares Plunge

CNBC.com
Wednesday, 7 Mar 2007 | 11:26 AM ET

Shares of CV Therapeutics plummeted following the company's announcement late Tuesday that its angina drug ranolazine was not effective in a study of acute and long-term treatment of patients with a type of heart disease known as acute coronary syndrome.

Wednesday's drop came on top of the shares losing more than a quarter of their value in after-market trading Tuesday.

There was no adverse trend in death or arrhythmias in patients taking the drug, also known by the chemical name ranolazine, the company said.

CV Therapeutics said it believes the data could support expansion of the drug's approved uses to be included as a first choice treatment for angina. It is currently approved to treat chronic angina in patients who have not achieved an adequate response with other drugs.

Featured

Contact U.S. News

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    › Learn More

Don't Miss

U.S. Video

  • Mad Money's Jim Cramer discusses Micron Technology and how the company gained control over inventory issues. The bears expect the company's history to repeat itself, but Cramer says this time, it feels different.

  • In this excerpt from a live CNBC interview, Warren Buffett explains why it's extremely unusual for a company's directors to vote against executive compensation plans.

  • Mad Money host Jim Cramer says shareholder activism works for every shareholder, and offers his take on the Valeant/Bill Ackman bid to acquire Allergan. The market is better off for these efforts, he says.